

*For Immediate Release:
January 15, 2005
Cambridge, MA*

*Contact:
Bill Hayden, Senior Vice President
514-895-2455
bill@coalesix.com*

Coalesix Announces Closing of Series A Funding Round

(January 15, 2005, Cambridge, MA) -- As a confirmation of the strength of its mission to improve the efficiency of drug discovery, Coalesix today announced it successfully closed its Series A round of financing.

The round was fully subscribed, resulting in common stock investment by a major pharmaceutical company and a well-known computer technology entrepreneur.

In addition to making an equity investment, the pharmaceutical company entered into a commercial agreement with Coalesix to cover utilization and further licensing of the Coalesix technology platform.

According to Coalesix President and CEO Paul Edwards, the successful funding round will help the company continue its development of a drug discovery technology environment aimed at shortening the Lead-to-Candidate phase of drug discovery.

“This round of funding should provide the company with the necessary resources to fully build out its environment and broaden its availability to the drug discovery community,” said Edwards.

The combined knowledge of Coalesix’s investors will also assist the company in its mission. “Our investors’ expertise in the pharmaceutical sector and technology base is expected to be invaluable,” said Edwards.

Headquartered in Cambridge, MA, Coalesix focuses on the development and commercialization of technology to improve the efficiency of drug discovery through the use of its *Mobius* Candidate Design Environment (CDE). *Mobius* offers drug discovery organization the ability to maximize the return on all of their Lead optimization efforts and resources while at the same time helping overcome the lead-to-candidate bottleneck. The *Mobius* CDE fosters interactions between computational and medicinal chemistry to

produce a novel approach to address the challenges of Lead Optimization in order to enable faster identification of more potential drug candidates.

More information on Coalesix and the *Mobius* CDE can be obtained by contacting Bill Hayden, Senior Vice President, at 514-895-2455 or bill@coalesix.com